Polypeptide aggregate-polyphenol polysaccharide network drug delivery system and application thereof

The loading of curcumin through the polypeptide condensate-polyphenol polysaccharide network system solves the problems of low load efficiency of traditional drug delivery systems, achieves pH-responsive sustained release and antibacterial effects, and provides new for skin defect wound healing Treatment pathway.

CN118903440APending Publication Date: 2024-11-08SICHUAN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411345022.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Traditional drug delivery systems have problems of premature drug release, poor stability and low load efficiency, and the synthesis of nanoparticles is complex and may cause adverse reactions.

Method used

Using polypeptide condensate-polyphenol polysaccharide network system, the condensate formed by arginine oligopeptide, aspartic acid oligopeptide, tannic acid and carboxymethyl chitosan is loaded with curcumin to achieve pH-responsive sustained release , enhance stability and antibacterial activity.

Benefits of technology

It improves the stability and responsiveness of the drug delivery system, achieves the precise release and antibacterial effect of the drug, has a positive effect on the healing of skin defect wounds, and has good cell penetration ability and biocompatibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903440A_ABST
    Figure CN118903440A_ABST
Patent Text Reader

Abstract

The invention relates to a polypeptide aggregate-polyphenol polysaccharide network drug delivery system and a preparation method thereof, and belongs to the technical field of biological medicine. The invention provides a polypeptide aggregate-polyphenol polysaccharide network drug delivery system, which comprises an aggregate inner core formed by arginine oligopeptide and aspartic acid oligopeptide and a polyphenol polysaccharide network formed by tannic acid and carboxymethyl chitosan, the system has the advantages of microenvironment responsiveness, strong drug loading and transporting capability, capability of keeping biomolecule activity, good cell penetrating capability, simple and convenient synthesis path and good biocompatibility. Taking treatment of skin defects as an example, the hydrogel has antibacterial activity and capability of removing reactive oxygen species (ROS) in in-vitro epidermis cells, has huge potential in the aspects of reducing oxidative stress and promoting wound healing, has huge application potential as a drug delivery system, and can be combined with hydrogel to be applied to the fields of skin injury repair and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a polypeptide aggregate-polyphenol polysaccharide network drug delivery system and application thereof, belonging to the technical field of biomedicine. Background Art

[0002] Coacervates (Coa) are a form of nanoparticles that have recently attracted widespread attention. Traditional drug delivery systems have disadvantages such as poor cyclic stability, premature drug release, and lack of responsiveness. Premature or excessive drug release often occurs, and accurate drug delivery and optimization of therapeutic effects cannot be achieved. Although microenvironment-responsive drug delivery systems have been preliminarily applied in a variety of diseases, the synthesis process of these nanoparticles is complicated, and they mainly achieve drug loading through passive adsorption of drugs, with low loading efficiency; in addition, the raw materials for synthesizing nanoparticles only act as carriers, and may cause adverse reactions in the body after accumulation. Coacervates refer to a dense liquid-like condensate formed by liquid-liquid phase separation of high-concentration biomolecules based on multiple interactions (electrostatic interactions, hydrophobic interactions, π stacking, and hydrogen bonding, etc.). The particle size of the coacervate is at the nanometer or micrometer level, and it looks like an emulsion but does not require stabilizing molecules such as surfactants. The coacervate concentrates and encapsulates the drug inside, and the release of the drug is achieved by controlling the properties of the coacervate. As a drug delivery platform, coacervate has unique advantages, can encapsulate and deliver biomolecules such as proteins, DNA and RNA, and its advantages include rapid and effective loading of therapeutic drugs, protective effects on loads, unstable enzymes or drugs can be encapsulated inside coacervate, thereby isolating from the external environment, etc. However, coacervate as a drug delivery system still faces stability problems during long-term storage and use, and bad chemical or physical environments may have an adverse effect on its performance. The present invention selects a protective and responsive polyphenol polysaccharide network (PPN) to be combined with it to improve the stability and delivery effect of coacervate. Coacervate can be used as a nanoreactor or nanocarrier loaded with antimicrobial active substances, and has high cell compatibility, and has a high potential application value in the field of antibacterial. The present invention provides a pH-responsive antibacterial coacervate, which has a polypeptide coacervate core and a polyphenol polysaccharide coating, specifically formed by arginine oligopeptide, aspartic acid oligopeptide, tannic acid (TA) and carboxymethyl chitosan (CMC), denoted as Coa, and further loaded with curcumin (Cur) Coa denoted as CurCoa. This coacervate shows antibacterial activity and the ability to scavenge reactive oxygen species (ROS) in epidermal cells in vivo. Summary of the invention

[0003] The purpose of the present invention is to solve the technical problem of how to obtain a polypeptide aggregate-polyphenol polysaccharide network drug delivery system and its application.

[0004] In order to achieve the purpose of solving the above-mentioned problems, the technical solution adopted by the present invention is to provide a polypeptide aggregate-polyphenol polysaccharide network drug delivery system, wherein the delivery system includes an aggregate formed by arginine oligopeptide, aspartic acid oligopeptide, tannic acid and carboxymethyl chitosan; wherein the number of oligopeptides on the arginine oligopeptide and aspartic acid oligopeptide chains is not less than 5; the aggregate can be loaded with substances to be delivered; the substances include drugs.

[0005] The polypeptide aggregate-polyphenol polysaccharide network drug delivery system prepared in the embodiment of the present invention is loaded with the hydrophobic drug curcumin, which can respond to the acidic microenvironment to release curcumin slowly, exert anti-inflammatory and antibacterial effects, and promote the healing of infected skin defects.

[0006] Preferably, the delivery system comprises a polypeptide aggregate core formed by arginine oligopeptide and aspartic acid oligopeptide and a polyphenol polysaccharide network shell formed by tannic acid and carboxymethyl chitosan; wherein, arginine oligopeptide and aspartic acid oligopeptide form multiple hydrogen bonds and maintain their structure through hydrophobic and electrostatic interactions, and the structures of polyphenols, polysaccharides and polypeptide side groups are maintained through multiple cross-linking interactions such as hydrogen bonds, and the polyphenol polysaccharide network itself serves as both a part of the drug carrier and a drug active ingredient, and the aggregate having the effect of treating or preventing diseases is loaded with substances to be delivered; the substances include drugs.

[0007] The invention provides a preparation method of a polypeptide coacervate-polyphenol polysaccharide network drug delivery system. The preparation method comprises gradually adding arginine oligopeptide, aspartic acid oligopeptide, tannic acid and carboxymethyl chitosan to prepare coacervate nanoparticles in a Tris buffer.

[0008] Preferably, the preparation method comprises dissolving arginine oligopeptide in water; dissolving aspartic acid oligopeptide in DMSO, and then adding Tris buffer; then mixing the arginine oligopeptide solution and the aspartic acid oligopeptide solution in a molar ratio of 1:2 to obtain a coacervate as the core structure of the drug delivery system; then, adding tannic acid and carboxymethyl chitosan to the coacervate suspension to form a polyphenol polysaccharide shell that wraps the coacervate core. The molar ratios of tannic acid and carboxymethyl chitosan to the above-mentioned oligopeptide solution are 1:3 and 1:1, respectively; the pH value of the suspension is increased by adding Tris buffer solution; and the coacervate is collected by centrifugation.

[0009] The present invention provides an application of a polypeptide aggregate-polyphenol polysaccharide network drug delivery system in non-diagnostic methods and non-therapeutic methods.

[0010] Preferably, the application includes application in the preparation of medicines.

[0011] Preferably, the drug comprises a skin repair drug.

[0012] Preferably, the application includes application in preparing cosmetics.

[0013] Preferably, the application includes application in the preparation of personal skin protection products.

[0014] The present invention provides a drug carrier, wherein the carrier comprises the above-mentioned polypeptide aggregate; the carrier comprises a stent, a dressing or a coating and the like.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] The present invention uses chemical synthesis, firstly utilizes electrostatic interaction, hydrophobic interaction and hydrogen bond etc. between positively charged arginine oligopeptide and negatively charged aspartic acid oligopeptide to form coagulation in solution, and efficiently captures goods.On this basis, utilize multiple cross-linking interactions between polyphenol and polysaccharide, polypeptide side group, wrap a layer of polyphenol polysaccharide network on coagulation surface, greatly improve the stability, microenvironment responsiveness and operability of coagulation, construct a kind of novel polypeptide coagulation-polyphenol polysaccharide network drug delivery system, this structure is while maintaining the characteristics of coagulation efficient and rapid capture of goods, and synthetic raw material tannic acid and polysaccharide can play antibacterial and anti-inflammatory effect, realize the dual efficacy of carrier and active pharmaceutical ingredient.Polypeptide coagulation-polyphenol polysaccharide network drug delivery system has microenvironment responsiveness, powerful drug loading and transporting capacity, keeps biological molecule activity, good cell penetration ability, simple synthesis path and good biocompatibility. Taking the treatment of skin defects as an example, it shows antibacterial activity and the ability to scavenge reactive oxygen species (ROS) in epithelial cells in vivo; it has a positive effect on skin wound healing; it provides a new treatment approach for skin repair and has important clinical significance for skin damage repair and skin health protection. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is the preparation and characterization diagram of the coacervate Coa.

[0018] Figure a is a schematic diagram of the Coa formation process; Figure b is a particle size distribution diagram of Coa; Figure c is a scanning electron microscope (SEM) image of Coa; Figure d is a fluorescence microscope image of Coa loaded with rBSA (top) and Cur (bottom); Figure e is a release curve of Cur from CurCoa under acidic (pH 6.0) and physiological (pH 7.4) conditions.

[0019] Figure 2 TEM image and EDX element image of Coa.

[0020] Figure 3 UV-visible spectra of R10, D10, TA, CMC and their combination.

[0021] Figure 4 The encapsulation efficiency of Cur and rBSA in Coa is shown in Figure 2; the data are shown as mean ± standard deviation (n = 3).

[0022] Figure 5 SEM images of Coa loaded with Cur (left) and rBSA (right).

[0023] Figure 6 Figure 3 is the particle size distribution diagram of Coa loaded with Cur and rBSA.

[0024] Figure 7 The release curves of rBSA from rBSACoa under acidic (pH 6.0) and physiological (pH 7.4) conditions are shown; the data are expressed as mean ± SD (n = 3).

[0025] Figure 8 SEM images of Escherichia coli and Staphylococcus aureus treated with Coa and CurCoa.

[0026] Fig. 9 Figure 2 shows the CFU images (a) and CFU counts (b) of Staphylococcus aureus and Escherichia coli on LB agar plates after incubation with Coa or CurCoa for 4 h at 37°C.

[0027] Fig.10 Live-dead fluorescence images of Escherichia coli and Staphylococcus aureus after incubation with Coa or CurCoa.

[0028] Fig.11 Figure 2 is the survival rate of HaCaTs treated with R10, D10, TA, CMC, Cur or their combination for 24 hours.

[0029] Fig.12 Live-dead staining of HaCaTs treated with R10, D10, TA, CMC, Cur or their combination for 24 h.

[0030] Fig.13 Fluorescence microscopy images of HaCaTs incubated with CurCoa (green). The cytoskeleton was stained with AlexaFluor 555phalloidine (red), and the nucleus was stained with DAPI (blue).

[0031] Fig.14 This figure shows the regulatory effect of CurCoa on wound healing in vitro.

[0032] a) Evaluation of ROS in HaCaTs after different treatments using DCFH-DA (green) probe. Cell nuclei were stained with DAPI.

[0033] Figure b shows the quantitative statistical graph of the fluorescence intensity of ROS in HaCaTs after different treatments detected by DCFH-DA fluorescent probe.

[0034] Fig.15 This is the DPPH (1,1-diphenyl-2-trinitrophenylhydrazine) radical scavenging activity diagram of Coa.

[0035] Fig.16 A diagram showing the regulatory effects of the combination of CurCoa, adipose tissue apoptotic vesicles and GelMa hydrogel on the healing of infected wounds in vivo.

[0036] Fig.17 This is a tissue section staining image of skin wound healing using a combination of CurCoa, adipose tissue apoptotic vesicles and GelMa hydrogel. DETAILED DESCRIPTION

[0037] In order to make the present invention more clearly understood, a preferred embodiment is described in detail with reference to the accompanying drawings as follows:

[0038] Example

[0039] 1. Preparation of CurCoa:

[0040] Coa nanoparticles ( Figure 1 a);

[0041] Arginine (R10) oligopeptide at 1.4 mg mL -1 Aspartic acid (D10) oligopeptide was dissolved in DMSO to a concentration of 10 mg mL -1 , and then added to Tris buffer (5 mM, pH 8.5) to a final concentration of 1.0 mg mL -1 The aggregates were prepared by mixing R10 and D10 in a molar ratio of 1:2 in 20 μL of water. Then, 10 μL of tannic acid (TA) (1.0 mg mL -1 ) and 20 μL carboxymethyl chitosan (CMC) (1.0 mg mL -1 ) was added to the coacervate suspension. The pH of the suspension was increased by adding 30 μL Tris buffer solution (10 mM, pH 8.5). After incubation for 10 seconds, Coa was collected by centrifugation (1500 g, 3 minutes) and washed twice with water. The Coa dispersion was stored at 4 ° C for further use.

[0042] To obtain CurCoa or rBSACoa, 2 μL of Cur (0.2 mg mL -1 ) or rhodamine B isothiocyanate-labeled bovine serum albumin (rBSA) (1 mg mL -1 ) was mixed with 10 μL of R10.

[0043] 2. Characteristics of CurCoa:

[0044] Dynamic light scattering (DLS) and zeta potential measurements were performed on a Zetasizer Nano ZSP. Figure 6 As shown; scanning electron microscope (SEM) images were obtained using JSM-7610F of JEOL Co., Ltd. of Japan at an operating voltage of 10 kV, as shown Figure 1 c, Figure 5 Transmission Electron Microscope (TEM) images and Energy Dispersive X-Ray Spectroscopy (EDX) spectra were obtained using a Thermo Fisher Talos F200S instrument at 200 kV. Figure 2 UV-Vis absorption and fluorescence spectra were measured on a Biotek Synergy H1 instrument. Figure 3 Brightfield and fluorescence images were captured on an Olympus IX73 inverted microscope.

[0045] The diameter of the obtained Coa is 101.3±5.6nm, such as Figure 1 b; Energy dispersive X-ray spectroscopy (EDX) element map shows, such as Figure 2 , Coa is composed of C, N and O elements. The UV-visible spectrum shows that Figure 3 The mixture of oligopeptides, TA and CMC increased the scattering in the visible light region, proving the successful formation of condensed nanoparticles. Considering that the large amount of ROS produced in the wound microenvironment can affect wound healing, the present invention also studied the antioxidant properties of Coa; Coa has the ability to scavenge free radicals in vitro, indicating that the phenolic hydroxyl group of Coa has a potential positive effect on wound healing; Fig.15 .

[0046] 3. CurCoa encapsulation efficiency and CurCoa drug release efficiency:

[0047] Before adding D10, TA, and CMC, 2 μL of Cur (25, 50, 75, 100, or 200 μg mL -1 ) was mixed with 10 μL of R10 and loaded into CurCoa. The encapsulation efficiency of Cur in CurCoa was determined by subtracting the loading amount from the total amount of cargo added. Fluorescence intensity at 600 nm was measured on equal volumes of supernatant obtained from the initial centrifugation step with an excitation wavelength of 560 nm to determine the unloaded amount. Using the same protocol, the fluorescence intensity of different concentrations of rBSA (0.2, 0.4, 0.6, 0.8, or 1.0 mg mL -1 ) of rBSACoa; Figure 4 As shown;

[0048] Loading different cargoes further enriches and expands the functionality of Coa. We validated the loading capacity of Coa on the hydrophilic protein rhodamine B isothiocyanate-labeled bovine serum albumin (rBSA) and the hydrophobic drug Cur. Figure 1 d, Figure 4 ; Demonstrated the versatility of Coa in delivering different types of cargo. -1 At the concentration of , the encapsulation efficiency of rBSA (90.5±0.3%) was higher than that of Cur (34.8±3.7%). Figure 4 This may be due to the better compatibility, solubility and intermolecular forces between hydrophilic proteins and water aggregates. After loading drugs of different molecular weights, the size of Coa also changed, ranging from 91.3nm to 458.7nm, such as Figure 5 and Figure 6 , which is positively correlated with the molecular weight of the cargo, indicating that the cargo is integrated into the coacervate.

[0049] In addition, the pH-responsive release profiles of CurCoa under different pH conditions (pH 7.4 or 6.0) were monitored. Phosphate buffer (PB) buffers at pH 7.4 and 6.0 were used to simulate the microenvironment of the normal physiological environment and the extracellular inflammatory microenvironment. Figure 1 As shown in e, the release rate of Cur in an acidic environment (25.5±0.9%) was higher than that in a neutral environment (11.8±1.0%). Similar results were observed for rBSA. Figure 7 ; This result can be attributed to the change in hydrogen bond strength caused by the deprotonation of phenolic hydroxyl groups in polyphenols.

[0050] The release efficiency of CurCoa at different pH values ​​(pH 6.0 and pH 7.4) was tested. Specifically, 2 μL Cur (0.2 mg mL -1) was mixed with 10 μL R10 to be loaded in CurCoa. The supernatant after centrifugation (1500 g, 3 minutes) was collected, and the supernatant was collected on days 1, 2, and 3. The concentration of Cur released in the supernatant (i.e., OD) was measured using a microplate reader. The drug release efficiency was calculated as follows:

[0051]

[0052] Among them A total , A after released and A blank The OD of the supernatant obtained after complete release of CurCoa, the OD of the supernatant obtained after centrifugation at different times, and the OD of the original solution are respectively. Using the same protocol, we studied the release behavior of rBSACoa at pH 6.0 and pH 7.4; Figure 7 shown.

[0053] 4. Antimicrobial activity of Coa and CurCoa:

[0054] The antibacterial activities of Coa and CurCoa against Staphylococcus aureus and Escherichia coli were tested using bacterial colony morphology analysis, live-dead cell staining and colony formation assays.

[0055] 100 μL of bacterial suspension and 20 μL of Coa and CurCoa were added to 1 mL of LB medium and incubated for 24 h before subsequent testing.

[0056] Bacterial morphology determination: 100 μL of treated bacteria were diluted in 1 mL of LB medium and then fixed with 2.5% glutaraldehyde. After washing, dehydration and drying, the bacterial morphology was observed by SEM, such as Figure 8 ;

[0057] Live / dead staining: 100 μL of treated bacteria were diluted in 1 mL of LB medium. Bacterial Viability Assay Kit was used to perform live / dead staining of treated bacteria. Images were collected by inverted fluorescence microscopy. Fig.10 ;

[0058] Colony formation assay: dilute the treated bacteria by 10 7 10 μL of the diluted bacteria were spread on an agar plate. After culturing at 37°C for 24 h, the plate image was observed by a chemiluminescent gel imager (ChemiDoc, Bio-rad, America), and the colony forming units (CFU) were counted using ImageJ image processing software. Fig. 9 ;

[0059] Skin infections are often closely associated with Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus). These two bacteria were used as models to evaluate the antibacterial effects of Cur and CurCoa. Scanning electron microscopy (SEM) results showed that Staphylococcus aureus and E. coli treated with CurCoa showed structural ruptures, and the number of ruptures in the CurCoa group was greater than that in the Coa group, such as Figure 8 The results of CFU (colony forming unit test) confirmed that the number of viable Staphylococcus aureus and Escherichia coli colonies in the CurCoa treatment group was the lowest. Fig. 9 b. Live and dead bacteria staining results showed that the proportion of dead Staphylococcus aureus and Escherichia coli was significantly higher after CurCoa treatment. Fig.10 .

[0060] The antibacterial effect of CurCoa was studied by CFU experiments. The results showed that both Cur and CurCoa showed effective antibacterial activity against Staphylococcus aureus and Escherichia coli, with the least bacterial colonies produced after treatment, indicating that CurCoa can resist bacterial infection through the components that make up Cur (such as TA, CMC) and drug release.

[0061] 5. Biocompatibility of Coa and CurCoa:

[0062] Since CurCoa is designed to be used in the human epidermis in the future, we evaluated its biocompatibility using human keratinocytes (HaCaTs), the primary cell of the epidermis.

[0063] After treating HaCaTs with CurCoa, live-dead staining and CCK8 detection were performed, and the results consistently showed that CurCoa had good biocompatibility, such as Fig.11 and Fig.12 .

[0064] 6. In vitro reactive oxygen species (ROS) scavenging test:

[0065] The ROS scavenging ability of CurCoa was detected by 2,7-dichlorofluorescein diacetate (DCFH-DA).

[0066] HaCaTs were plated at 1 × 10 per well. 5Cells were seeded into 24-well plates at a rate of 100 μL and cultured overnight in the H2O2 group (500 μL DMEM per well) and the H2O2+CourCoa group (500 μL DMEM containing CurCoa per well). Then they were incubated with 100 μM H2O2 for 2 hours. The supernatant was removed and 500 μL DCFH-DA was added to each well for continuous incubation. The fluorescence of the cells was imaged by an inverted fluorescence microscope. The fluorescence intensity was evaluated by flow cytometry. Cells without any treatment were used as a blank group.

[0067] High levels of ROS can affect wound healing because they cause oxidative damage to cells and tissues, delaying the healing process. We exploited the antioxidant properties of polyphenols and Cur to mitigate the effects of ROS. In our study, we first verified the uptake of CurCoa by HaCaTs. Using fluorescence microscopy, we observed strong fluorescence signals in the cytoplasm of HaCaTs, indicating successful internalization of CurCoa, as shown in Figure 2. Fig.13 Subsequently, we used the fluorescent probe DCFH-DA to detect intracellular ROS levels. After treating the cells with H2O2, a significant increase in green fluorescence (indicating the generation of ROS) was observed. In contrast, the introduction of CurCoa reversed the H2O2-induced fluorescence increase, demonstrating their significant intracellular ROS scavenging ability, as shown in Figure 2. Fig.14 . Flow cytometry results showed that after H2O2 treatment, 95.6% of the cells had significantly increased intracellular ROS levels. However, after CurCoa treatment, this proportion dropped to 47.0%. The results of the study indicate that CurCoa is effectively internalized by cells and exhibits significant intracellular ROS scavenging ability. CurCoa has great potential in both reducing oxidative stress and promoting wound healing, making it a promising candidate for future therapeutic applications.

[0068] 7. Test to promote wound healing in vivo:

[0069] Since curcumin-loaded Coa (CurCoa) has acidic microenvironment responsiveness and antibacterial activity, it can be used to treat infected skin defects. We simultaneously loaded CurCoa and apoptotic vesicles (ApoEVs) that can promote angiogenesis / cell migration into GelMa hydrogel for the treatment of infected skin defects. First, a full-thickness skin defect model infected with Staphylococcus aureus was constructed, and the wounds were treated with GelMA, CurCoa-GMA, ApoEV-GMA and CurCoa-ApoEV-GMA, respectively. After 15 days of treatment, the wounds in the CurCoa-ApoEV-GMA scaffold group were almost completely healed, with a healing rate of 100%, while 21.0%, 19.0%, 11.9% and 11.6% of the wound areas in the blank group, GelMA group, CurCoa-GMA group and ApoEV-GMA group, respectively, were not healed, and the number of colonies after CurCoa-ApoEV-GMA treatment was significantly reduced, such as Fig.16 The histological images after H&E staining and Masson staining showed that the re-epithelialization rate and the number of blood vessels in the CurCoa-GMA group and ApoEV-GMA group were higher than those in the blank group and GelMA group. Fig.17 These results indicate that CurCoa can effectively reduce the risk of infection and create a favorable microenvironment for wound healing, which is crucial for the healing of infected full-thickness skin wounds.

[0070] The above is only a preferred embodiment of the present invention, and is not any formal or substantial limitation of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention. Any technician familiar with this profession, without departing from the spirit and scope of the present invention, can make some changes, modifications and equivalent changes made by using the technical content disclosed above, which are equivalent embodiments of the present invention; at the same time, any changes, modifications and evolutions of any equivalent changes made to the above embodiments based on the essential technology of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. A polypeptide aggregate-polyphenol polysaccharide network drug delivery system, characterized in that: The delivery system comprises a coacervate formed by arginine oligopeptide, aspartic acid oligopeptide, tannic acid and carboxymethyl chitosan; wherein the number of oligopeptides on the arginine oligopeptide and aspartic acid oligopeptide chains is not less than 5; the coacervate can be loaded with substances to be delivered; the substances include drugs.

2. A polypeptide aggregate-polyphenol polysaccharide network drug delivery system according to claim 1, characterized in that: The delivery system comprises a polypeptide aggregate core formed by arginine oligopeptide and aspartic acid oligopeptide and a polyphenol polysaccharide network shell formed by tannic acid and carboxymethyl chitosan; the polyphenol polysaccharide network itself serves as both a part of the drug carrier and an active drug component.

3. A method for preparing a polypeptide aggregate-polyphenol polysaccharide network drug delivery system, characterized in that: The preparation method comprises the steps of gradually adding arginine oligopeptide, aspartic acid oligopeptide, tannic acid and carboxymethyl chitosan to prepare condensate nanoparticles in a Tris buffer.

4. The preparation method according to claim 3, characterized in that: The preparation method comprises dissolving arginine oligopeptide in water; dissolving aspartic acid oligopeptide in DMSO, and then adding Tris buffer; then mixing the arginine oligopeptide solution and the aspartic acid oligopeptide solution in a molar ratio of 1:2 to obtain a coacervate as the core structure of the drug delivery system; then, adding tannic acid and carboxymethyl chitosan to the coacervate suspension to form a polyphenol polysaccharide shell that wraps the core of the coacervate. The molar ratios of tannic acid and carboxymethyl chitosan to the above-mentioned oligopeptide solution are 1:3 and 1:1 respectively; the pH value of the suspension is increased by adding Tris buffer solution; and the coacervate is collected by centrifugation.

5. Use of the polypeptide aggregate-polyphenol polysaccharide network drug delivery system according to claim 1 in non-diagnostic methods and non-therapeutic methods.

6. The use according to claim 5, characterized in that: The application includes application in preparing medicines.

7. The use according to claim 6, characterized in that: The drugs include skin repair drugs.

8. The use according to claim 5, characterized in that: The application includes application in preparing cosmetics.

9. The use according to claim 5, characterized in that: The application includes application in preparing personal skin protection products.

10. A drug carrier, characterized in that The carrier includes a polypeptide aggregate according to claim 1; the carrier form includes a stent, a dressing or a coating.

Citation Information

Cited By

  • Agglomerate-metal polyphenol network drug delivery system as well as preparation method and application thereof

    CN121041452A